SCHEMBL4595703

SCHEMBL4595703

Cc1cc(Br)c(C#N)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14986261 0.76
SCHEMBL95334 0.76
SCHEMBL13568091 0.74 TSHR (0.34)
SCHEMBL2614492 0.74
SCHEMBL21653333 0.73
SCHEMBL11520288 0.73
SCHEMBL2417707 0.73
SCHEMBL22833057 0.72 MME (0.44)
SCHEMBL18122960 0.72 PGR (0.39)
SCHEMBL31261454 0.69 MME (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
EP-1539731-B9 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-08-20 EP disclosed
US-7329686-B2 Substituted thiophene compounds ASTRAZENECA AB (SE) 2008-02-12 US disclosed
EP-1539731-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-01-02 EP disclosed
US-20060019999-A1 Specific inhibitors of one or more isoforms of nitric oxide synthase; 3-[[2-amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile; antiinflammatory agent; pain ASTRAZENECA AB (SE) 2006-01-26 US disclosed
US-20050203172-A1 Novel compounds ASTRAZENECA AB (SE) 2005-09-15 US disclosed
EP-1539731-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004009580-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-01-29 WO disclosed